Updated:
AmorChem
AmorChem is a leading early stage venture fund dedicated to creating the next generation of biotech companies from academic research. Since 2011, it has...
Overview
AmorChem is a leading early stage venture fund dedicated to creating the next generation of biotech companies from academic research. Since 2011, it has financed over 30 research programs in academia and accelerated the creation of several biotech companies. It focuses on translational research to bridge the innovation gap from fundamental academic research into next generation biotech companies, and aims to be the premier early-stage venture fund in Canada.
General information
Firm type
Private Equity
Year founded
2011
AUM
$87M
Location
Region
North America
Country
Canada
City
Montréal
Corporate office
Westmount, Canada
Principals
Dr. Kevin McBride
General Partner
Sector focus
Frequently asked questions
How does AmorChem source its investment opportunities?
The firm's entire model relies on proximity to Canadian universities and research hospitals. It identifies licensable therapeutic programs inside academic labs that have strong intellectual-property positions but lack commercial infrastructure. Deals are sourced through ongoing relationships with technology-transfer offices and principal investigators, not through GP-led auctions or inbound broker decks.
What investment stages does AmorChem target?
AmorChem concentrates on the gap between academic discovery and institutional venture capital — seed, start-up, and early-stage programs. The strategy also includes growth-position follow-ons and divestiture opportunities when a therapeutic asset requires a structured exit or a spin-off into a new entity. The firm does not operate a late-stage or pre-IPO vehicle.
What is AmorChem's geographic focus?
Portfolio formation is anchored in Canadian academic centers, particularly in Quebec and Ontario. As companies mature and require syndicated US financing, AmorChem facilitates cross-border exposure, often bringing in Boston- or Bay Area-based venture partners for follow-on rounds.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: